Medscape | New CLL Drug Delays Disease by Nearly 1 Year Medscape Obinutuzumab, which is indicated for use in combination with chlorambucil for patients with previously untreated CLL, improved median progression-free survival by nearly a year more than rituximab (Rituxan, Genentech) in a head-to-head trial of CLL ... |
